PHERECYDES, a biotechnology company specializing in precision phage therapy to treat resistant and/or complicated bacterial infections, agreed to acquire ERYTECH, a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells. Financial terms were not disclosed. “Our board of directors fully supports this transaction and is convinced that ERYTECH and PHERECYDES will gather critical expertise and capabilities enabling to boost our research programs, as well as a seasoned and very complementary management team, and an international position providing access to US investors and stakeholders. All these assets will also drive and accelerate PHERECYDES clinical development plan with controlled and randomized international trials to demonstrate clinical evidence of the phage therapy as a real game changer in the anti-infectious area. With my entire Management team we are eager to start working together with our ERYTECH colleagues.” Thibaut du Fayet, PHERECYDES Chief Executive Officer.